Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.15)
# 3,285
Out of 4,413 analysts
9
Total ratings
25%
Success rate
-37.77%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $43.82 | +9.54% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $4 → $3 | $0.99 | +203.03% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $52.05 | +49.86% | 1 | Aug 3, 2022 | |
| BNOX Bionomics | Initiates: Outperform | $17 | $0.95 | +1,689.47% | 1 | Jan 10, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | n/a | $13.26 | - | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | n/a | $6.24 | - | 1 | May 25, 2021 | |
| FNCH Finch Therapeutics Group | Initiates: Outperform | n/a | $2.22 | - | 1 | Apr 13, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $43.82
Upside: +9.54%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $4 → $3
Current: $0.99
Upside: +203.03%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $52.05
Upside: +49.86%
Bionomics
Jan 10, 2022
Initiates: Outperform
Price Target: $17
Current: $0.95
Upside: +1,689.47%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.26
Upside: -
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.24
Upside: -
Finch Therapeutics Group
Apr 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.22
Upside: -